Form 4: Pfizer Executive Sally Susman Modifies Stock Appreciation Rights

Executive Vice President Sally Susman modifies stock appreciation rights (SARs) in Pfizer, extending their vesting and settlement dates.

Summary

• Sally Susman, an Executive Vice President at Pfizer Inc., modified her stock appreciation rights (SARs) on September 12, 2024.
• The modification involves extending the vesting and settlement dates of certain outstanding SARs by two years.
• This was done through a one-time offer by Pfizer to modify eligible TSRUs (total shareholder return units).
• Susman elected to modify 43,624 SARs with an original exercisable date of February 23, 2028, extending it to February 23, 2030.
• She also modified 40,151 SARs with an original exercisable date of February 24, 2027, extending it to February 24, 2029.
• The grant price and the number of shares underlying the modified SARs remain unchanged.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document simply reports a modification of executive compensation, which is a routine corporate action. There are no indications of positive or negative implications for the company's performance.

Positives

• The modification of SARs provides Sally Susman with a longer timeframe for potential gains from Pfizer's stock performance.
• The extension of the vesting period may align Susman's incentives with the long-term performance of the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the extended vesting and settlement dates of the modified SARs.

Industry Context

Executive compensation, including stock appreciation rights, is a common practice in the pharmaceutical industry to align management's interests with shareholder value. Modifications to these rights can be influenced by company performance, market conditions, and strategic goals.

Comparison to Industry Standards

• Stock appreciation rights are a common component of executive compensation packages in large pharmaceutical companies like Johnson & Johnson, Merck, and AbbVie.
• The terms and conditions of these SARs, including vesting schedules and modification options, can vary widely based on company-specific policies and performance metrics.
• Extending vesting periods is sometimes used to incentivize long-term commitment and performance, similar to practices observed in other companies offering long-term equity incentives.

Stakeholder Impact

• The modification of executive compensation may have a minor impact on shareholder perception, depending on their views on executive pay and incentives.
• Employees may view the modification as a signal of the company's commitment to retaining key executives.

Key Dates